



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

VETERINARY MEDICINES IN 2025





Luxembourg: Publications Office of the European Union, 2026

Print	ISBN 978-92-9155-151-4	doi: 10.2809/6240990	TC-01-26-003-EN-C
PDF	ISBN 978-92-9155-150-7	doi: 10.2809/3675449	TC-01-26-003-EN-N

© European Medicines Agency, 2026

Reproduction is authorised provided the source is acknowledged. For any use or reproduction of images or other materials that are not under the copyright of the European Medicines Agency as specified subsequently, permission must be sought directly from the respective copyright holders. The indicated images or other materials are copyright protected and have been licenced by the European Medicines Agency via Adobe Stock, Dreamstime or iStockphoto, as shown respectively in the credit lines of each image or other material.

Cover image: © William | stock.adobe.com

Printed by the Publications Office of the European Union in Luxembourg

PRINTED ON 100% RECYCLED PAPER

AUTHORISATION OF NEW MEDICINES

Recommendations for the authorisation of new veterinary medicines in 2025 at a glance:



30

POSITIVE
OPINIONS



13

NEW ACTIVE
SUBSTANCES



0

NEGATIVE
OPINIONS



5

WITHDRAWN
APPLICATIONS

New veterinary medicines recommended for authorisation in 2025:

PRODUCT NAME	New active substance	Cats	Cattle	Chickens	Dogs	Ducks	Goats	Horses	Pigs	Sea breams	Sheep	Turkeys
BioBhyo	•								•			
Bluevac-3			•								•	
BRAVECTO CombiUNO					•							
CEVAC REOMUNE				•								
Ecovaxxin MS	•			•								
Elmaro		•			•							
Emevet					•							
Epizootic haemorrhagic disease vaccine (recombinant protein) Laboratorios Syva S.A.	•		•									
Firocoxib CP-Pharma					•							
Fluralaner Intervet					•							
Hemosyvet		•		•	•		•	•	•			
Hepizovac	•		•									
Innovax-ND-IBD-ILT	•			•								
Lenivia	•				•							
Nobilis Multiriva Gm+REOm				•								

PRODUCT NAME	New active substance	Cats 	Cattle 	Chickens 	Dogs 	Ducks 	Goats 	Horses 	Pigs 	Sea breams 	Sheep 	Turkeys 
Nobilis Multiriva IBm+ND				•								
Nobilis Multiriva IBm+ND+EDS				•								
Nobilis Multiriva IBm+ND+Gm+REOm +EDS				•								
Nobilis Multiriva REOm				•								
Numelvi	•				•							
Omeprazole TriviumVet					•							
Portela	•	•										
Prazivetin										•		
Prevestrus vet	•				•							
Syvazul BTV 3			•								•	
Varenzin	•	•										
Vaxxinact H5	•			•		•						•
Vaxxitek HVT+IBD+H5	•			•								•
Vectormune HVT-AIV				•								
Zenrelia	•				•							



INNOVATIVE VETERINARY MEDICINES AND VACCINES

BioBhyo

A new vaccine for the active immunisation of pigs against infections caused by *Brachyspira hyodysenteriae*.

Bluevac-3

A new vaccine for the active immunisation of sheep to reduce the viraemia (presence of viruses in the blood), mortality and clinical signs caused by the serotype 3 of the bluetongue virus. The vaccine is also intended for active immunisation of cattle to reduce the viraemia against the serotype 3 of the bluetongue virus.

CEVAC REOMUNE

A new vaccine for passive immunisation of broilers induced by active immunisation of broiler breeders to reduce clinical signs of tenosynovitis induced by avian reovirus infection.

Ecovaxxin MS

A new vaccine for the active immunisation of future layer and breeder chickens from 4 weeks of age to reduce air sac lesions, foot pad lesions (synovitis), ovarian regressions and egg production losses caused by *Mycoplasma synoviae* infections.

Epizootic haemorrhagic disease vaccine (recombinant protein) Laboratorios Syva S.A.

A new biotech vaccine for the active immunisation of cattle to reduce viraemia and fever caused by epizootic haemorrhagic disease virus serotype 8.

Hepizovac

A new vaccine for the active immunisation of cattle to prevent viraemia caused by epizootic haemorrhagic disease virus serotype 8.

Innovax-ND-IBD-ILT

A new biotech vaccine for the active immunisation of one-day-old chicks or 18-19 day-old embryonated chicken eggs to reduce mortality and clinical signs caused by Newcastle disease virus and to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis virus, Marek's disease virus and infectious bursal disease virus.



Nobilis Multiriva REOm

A new vaccine for the active immunisation of chickens and for passive immunisation of their progeny to reduce viraemia and clinical signs of disease caused by avian reovirus genotypes 1 and 4.

Nobilis Multiriva Gm+REOm

A new vaccine for the active immunisation of chickens and for passive immunisation of their progeny to reduce:

- mortality and clinical signs of disease caused by very virulent (CS89) and classical (STC) strains of infectious bursal disease virus;
- viraemia and clinical signs of disease caused by avian reovirus genotypes 1 and 4.

Legend:

 Cats  Cattle  Chickens  Dogs  Ducks  Pigs  Sea breams  Sheep  Turkeys

Nobilis Multiriva IBm+ND

A new vaccine for the active immunisation of chickens to reduce:

- respiratory signs and egg drop caused by infectious bronchitis virus strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype);
- mortality and clinical signs caused by Newcastle disease virus.

Nobilis Multiriva IBm+ND+EDS

A new vaccine for the active immunisation of chickens to reduce:

- respiratory signs and egg drop caused by infectious bronchitis virus strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype);
- mortality and clinical signs caused by Newcastle disease virus;
- egg drop and eggshell defects caused by egg drop syndrome-1976 virus.

Nobilis Multiriva IBm+ND+Gm+REOm+EDS

A new vaccine for the active immunisation of chickens to reduce:

- respiratory signs and egg drop caused by infectious bronchitis virus strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype);
- mortality and clinical signs caused by Newcastle disease virus;

The vaccine is also intended for the passive immunisation of their progeny to reduce:

- mortality and clinical signs of disease caused by very virulent (CS89) and classical (STC) strains of infectious bursal disease virus;
- viraemia and clinical signs of disease caused by avian reovirus genotypes 1 and 4;
- egg drop and eggshell defects caused by egg drop syndrome-1976 virus.

Prazivetin

A medicine for the treatment of ectoparasitic infestations of the gills of sea breams caused by monogenean trematodes principally of the species *Sparicotyle chrysophrii*.

Prevestrus vet

A medicine intended to shorten the pro-oestrus and oestrus period, reduce clinical signs of heat and reduce the risk of pregnancy in dogs (bitches).

Syvazul BTV 3

A new vaccine for the active immunisation of sheep to reduce viraemia, mortality, clinical signs and lesions caused by bluetongue virus serotype 3.

Varenzin

A medicine for the management of non-regenerative anaemia associated with chronic kidney disease in cats, by increasing haematocrit/ packed cell volume.

Vaxxinact H5

A new biotech vaccine for the following indications associated with highly pathogenic avian influenza serotype 5, including the circulating clade 2.3.4.4b:

- active immunisation to prevent mortality, clinical signs and to reduce viral excretion in chickens and mulard ducks;
- to reduce mortality, clinical signs and viral excretion in muscovy ducks and turkeys;
- to reduce viral excretion in pekin ducks.

Vaxxitek HVT+IBD+H5

A new biotech vaccine for:

- active immunisation of one-day-old chicks or 18-day-old embryonated chicken eggs to reduce mortality, clinical signs and virus excretion due to infection with highly pathogenic avian influenza virus of the H5 subtype, including the circulating clade 2.3.4.4b.
- active immunisation of one-day-old turkeys to reduce mortality, clinical signs and virus excretion due to infection with highly pathogenic avian influenza virus of the H5 subtype, including the circulating clade 2.3.4.4b.

Vectormune HVT-AIV

A new biotech vaccine for the active immunisation of one-day-old chickens to reduce mortality, clinical signs, and virus excretion due to infection with highly pathogenic avian influenza virus of the H5 subtype.

NEW USES FOR EXISTING MEDICINES

The use of an already authorised medicine in a new species or for a new indication offers new treatment opportunities. The use of 11 known products was expanded in 2025:



Bravecto TriUNO

To be also used for the treatment of infections with *Angiostrongylus vasorum* in dogs.

Credelio, Credelio Plus and Lotimax

To be also used for the treatment of sarcoptic mange (*Sarcoptes scabiei*) and by killing the vector *Dermacentor reticulatus*, the medicines reduce the risk of transmission of the vector-borne pathogen *Babesia canis canis* in dogs.

Daxocox

To be also used for the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery in dogs.

Dexdomitor 0.5 mg/ml solution for injection

To be administered intravenously as a constant rate infusion in dogs and cats as part of a multimodal protocol during inhalation anaesthesia.

Frontpro

To be also used for the treatment of tick infestation with *Hyalomma marginatum*, reduction of the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* for 30 days, and reduction of the risk of infection with *Babesia canis canis* via transmission by *Dermacentor reticulatus* for 28 days in dogs.

Nexgard and Nexgard spectra

To be also used for reduction of the risk of infection with *Babesia canis canis* via transmission by *Dermacentor reticulatus* for 28 days and for reduction of the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* for 30 days in dogs.

Stronghold Plus

To be also used for reduction of the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* for up to one month after treatment in cats.

Syvazul BTV 3

To be also used for the active immunisation of cattle to reduce viraemia caused by bluetongue serotype 3.

KEEPING MEDICINES SAFE

Once a medicine has been put on the market, EMA and European Union (EU) Member States continue to monitor its quality and benefit/risk balance.



Important safety procedures in 2025 included:

Bravecto chewable tablets

Amendment to the product information on potential side effects following administration of Bravecto chewable tablets, to include pruritus (itching).

Bravecto spot-on solution for cats

Amendment to the product information on potential side effects following the administration of Bravecto spot-on solution for cats, to include pruritus (itching) and ataxia (incoordination).

Bravecto spot-on solution for dogs

Amendment to the product information on potential side effects following administration of Bravecto spot-on solution for dogs, to include diarrhoea and pruritus (itching).

Divence IBR Marker Live, Divence Penta and Divence Tetra

Amendment to the product information on potential side effects following administration of Divence IBR Marker Live, Divence Penta, as well as Divence Tetra, to include milk production decrease, reduced food intake and decreased activity observed in dairy cows.

Eluracat

Amendment to the product information on potential side effects following administration of Eluracat, to include anorexia (loss of appetite), behavioural disorder, dyspnoea (difficulty breathing), loss of consciousness, sedation, recumbency (lying down), muscle weakness and hiding.

Felpreva

Amendment to the product information on potential side effects following administration of Felpreva, to change the frequency of application site reaction (e.g. scratching, erythema (reddening), hair loss, inflammation) from very rare to rare.

Librela

Amendment to the product information on potential side effects following administration of Librela, to include diarrhoea, emesis (vomiting), joint pain, lameness and swelling in multiple joints (immune-mediated polyarthritis), weakness (paresis), loss of movement (paralysis) and convulsion (seizure). In addition, special precautions should be taken when treating dogs with the following pre-existing conditions: low amounts of red blood cells (immune-mediated haemolytic anaemia), lameness and swelling in multiple joints (immune-mediated polyarthritis), low amounts of platelets (thrombocytes) (immune-mediated thrombocytopenia) or when treating dogs with pre-existing convulsion (seizure) disorder.

Mhyosphere PCV ID

Amendment to the product information on potential side effects following administration of Mhyosphere PCV ID, to change the frequency of elevated temperature from common to very common.

Neptra

Amendment to the product information on potential side effects following administration of Neptra, to include facial paralysis (loss of movement).

Osurnia

Amendment to the product information for Osurnia, to include new special precautions: in very rare cases, eye disorders such as neurogenic keratoconjunctivitis sicca, keratoconjunctivitis sicca, corneal ulcer, blepharospasm, eye redness and ocular discharge have been reported in treated dogs and ataxia (incoordination), internal ear disorder (mainly head tilt), facial paralysis and nystagmus (involuntary eye movements) have been reported in very rare cases in post-authorisation experience.

Yurvac RHD

Amendment to the product information on potential side effects following administration of Yurvac RHD, to include anorexia (loss of appetite) and intestinal stasis (inactivity).



© Milan | stock.adobe.com

MAXIMUM RESIDUAL LIMITS (MRL) RECOMMENDED IN 2025

Where a medicine is marketed for use in food-producing animals, any human safety concerns that might result from exposure to residues of the medicine remaining in animal-derived food need to be addressed.

The maximum residue limits (MRLs) recommended by EMA reflect how much residue of the veterinary medicine in food derived from a treated animal is safe for consumption. The MRL is established before the medicine for food-producing animals is authorised in the EU and entered in the annex to [Commission Regulation \(EU\) No 37/2010](#).

Positive opinions were adopted recommending the extension of MRLs for the following active substances in 2025:

- **Fluralaner**
extension to salmonidae and other fin fish
- **Lidocaine**
modification in porcine



European Medicines Agency

Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

☎ +31 (0)88 781 6000

www.ema.europa.eu



Publications Office
of the European Union

ISBN 978-92-9155-151-4